According to the Wegovy prescribing information, cholelithiasis occurred in approximately 1.6% of semaglutide-treated patients versus 0.7% in placebo groups
However, combination therapies must be individualized based on the patients specific clinical condition, allergen profile, symptom severity, physiological characteristics, and economic context under specialist guidance
In June last year, the Danish firm applied to Chinas drug regulator to widen the scope to include obesity, and this medical indication is expected to be approved this year
Obesity variants in the GIPR gene are not associated with risk of fracture or bone mineral density
However, most patients will start to lose weight the week of starting Glp-1 medical weight loss